Paper · 32053675
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
1 to 20 of 34
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19692680 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19692680 | PubMed |
| 2 | 28494184 | Current status of research and treatment for non-small cell lung cancer in never-smoking females. | Cancer Biol Ther | 2017 | https://conductscience.org/library/papers/28494184 | PubMed |
| 3 | 16818686 | Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/16818686 | PubMed |
| 4 | 24419411 | A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). | J Thorac Oncol | 2014 | https://conductscience.org/library/papers/24419411 | PubMed |
| 5 | 24908327 | Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis. | J Cancer Res Clin Oncol | 2014 | https://conductscience.org/library/papers/24908327 | PubMed |
| 6 | 27908825 | EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. | J Thorac Oncol | 2017 | https://conductscience.org/library/papers/27908825 | PubMed |
| 7 | 31384460 | Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer. | Mol Clin Oncol | 2019 | https://conductscience.org/library/papers/31384460 | PubMed |
| 8 | 24002608 | EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. | Br J Cancer | 2013 | https://conductscience.org/library/papers/24002608 | PubMed |
| 9 | 21841502 | Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. | J Thorac Oncol | 2011 | https://conductscience.org/library/papers/21841502 | PubMed |
| 10 | 25668120 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. | J Thorac Oncol | 2015 | https://conductscience.org/library/papers/25668120 | PubMed |
| 11 | 23558737 | The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. | BMJ Open | 2013 | https://conductscience.org/library/papers/23558737 | PubMed |
| 12 | 7521815 | Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. | Chest | 1994 | https://conductscience.org/library/papers/7521815 | PubMed |
| 13 | 25897154 | Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25897154 | PubMed |
| 14 | 16467097 | Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/16467097 | PubMed |
| 15 | 28599445 | Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations. | Oncol Lett | 2017 | https://conductscience.org/library/papers/28599445 | PubMed |
| 16 | 17167137 | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. | N Engl J Med | 2006 | https://conductscience.org/library/papers/17167137 | PubMed |
| 17 | 25558790 | The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. | Lung Cancer | 2015 | https://conductscience.org/library/papers/25558790 | PubMed |
| 18 | 24285021 | Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. | Ann Oncol | 2014 | https://conductscience.org/library/papers/24285021 | PubMed |
| 19 | 18403609 | EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. | J Mol Diagn | 2008 | https://conductscience.org/library/papers/18403609 | PubMed |
| 20 | 20573926 | Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20573926 | PubMed |
papers-2026-11-12-0.1.0
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/papers/v1/32053675/references